{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:57:15Z","timestamp":1791467835403,"version":"4.3.4"},"reference-count":55,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"unspecified","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1136\/openhrt-2026-004530","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:10:26Z","timestamp":1791465026000},"page":"e004530","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed left ventricular remodelling in patients with heart failure and reduced ejection fraction: a systematic review"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-7323","authenticated-orcid":false,"given":"Laurence","family":"Whittaker","sequence":"first","affiliation":[{"name":"Academic Cardiovascular Unit, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"},{"name":"Hull York Medical School, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visvesh","family":"Jeyalan","sequence":"additional","affiliation":[{"name":"Academic Cardiovascular Unit, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"},{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dewhurst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Northumbria Healthcare NHS Foundation Trust, North Shields, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chapman","sequence":"additional","affiliation":[{"name":"Academic Cardiovascular Unit, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brown","sequence":"additional","affiliation":[{"name":"Academic Cardiovascular Unit, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P","family":"Gale","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"},{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Uphoff","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Academic Cardiovascular Unit, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"},{"name":"Hull York Medical School, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806101914000_13.2.e004530.1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858"},{"key":"2026100806101914000_13.2.e004530.2","unstructured":"National Institute for Health and Care Excellence (NICE) . Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure [TA314]. 2014. Available: https:\/\/www.nice.org.uk\/guidance\/ta314"},{"key":"2026100806101914000_13.2.e004530.3","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.hrthm.2015.06.039","article-title":"A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model","volume":"12","author":"Shadman","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026100806101914000_13.2.e004530.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2026100806101914000_13.2.e004530.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013474"},{"key":"2026100806101914000_13.2.e004530.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043399"},{"key":"2026100806101914000_13.2.e004530.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608029"},{"key":"2026100806101914000_13.2.e004530.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac262"},{"key":"2026100806101914000_13.2.e004530.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.09.004"},{"key":"2026100806101914000_13.2.e004530.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab560"},{"key":"2026100806101914000_13.2.e004530.11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.943377","article-title":"Effect of sacubitril\/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026100806101914000_13.2.e004530.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12821"},{"key":"2026100806101914000_13.2.e004530.13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00228-021-03189-8","article-title":"Effect of SAcubitril\/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study","volume":"77","author":"Guerra","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026100806101914000_13.2.e004530.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01440-y"},{"key":"2026100806101914000_13.2.e004530.15","first-page":"5690","article-title":"Impact of sacubitril\/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience","volume":"25","author":"Monzo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026100806101914000_13.2.e004530.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.06.015"},{"key":"2026100806101914000_13.2.e004530.17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","article-title":"Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study","volume":"45","author":"Veltmann","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100806101914000_13.2.e004530.18","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000198","article-title":"A systematic review of ICD complications in randomised controlled trials versus registries: is our \u201creal-world\u201d data an underestimation?","volume":"2","author":"Ezzat","year":"2015","journal-title":"Open Heart"},{"key":"2026100806101914000_13.2.e004530.19","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.hrthm.2021.07.008","article-title":"Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience","volume":"18","author":"Gasperetti","year":"2021","journal-title":"Heart Rhythm"},{"key":"2026100806101914000_13.2.e004530.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab364"},{"key":"2026100806101914000_13.2.e004530.21","doi-asserted-by":"crossref","first-page":"105573","DOI":"10.1016\/j.phrs.2021.105573","article-title":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials","volume":"169","author":"Bao","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026100806101914000_13.2.e004530.22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028231","article-title":"Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials","volume":"100","author":"Lin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026100806101914000_13.2.e004530.23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026100806101914000_13.2.e004530.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026100806101914000_13.2.e004530.25","unstructured":"Centre for Reviews and Dissemination . Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. 2009. Available: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf"},{"key":"2026100806101914000_13.2.e004530.26","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2026100806101914000_13.2.e004530.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"2026100806101914000_13.2.e004530.28","unstructured":"Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, Available: www.covidence.org"},{"key":"2026100806101914000_13.2.e004530.29","unstructured":"Wells GA , Shea B . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2016. Available: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2026100806101914000_13.2.e004530.30","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002933","article-title":"Effect of optimisation to contemporary HFrEF medical therapy with sacubitril\/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study","volume":"11","author":"Zheng","year":"2024","journal-title":"Open Heart"},{"key":"2026100806101914000_13.2.e004530.31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00228-023-03527-y","article-title":"Effects of sacubitril\/valsartan on exercise capacity: a prognostic improvement that starts during uptitration","volume":"79","author":"Mapelli","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2026100806101914000_13.2.e004530.32","article-title":"Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data","volume":"7","author":"Frey","year":"2021","journal-title":"Cardiooncology"},{"key":"2026100806101914000_13.2.e004530.33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-021-03210-0","article-title":"Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients","volume":"78","author":"Corrado","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026100806101914000_13.2.e004530.34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020262","article-title":"Early Effects of Sacubitril\/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction","volume":"8","author":"Vitale","year":"2019","journal-title":"J Clin Med"},{"key":"2026100806101914000_13.2.e004530.35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061897","article-title":"Sacubitril\/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction","volume":"9","author":"Giallauria","year":"2020","journal-title":"J Clin Med"},{"key":"2026100806101914000_13.2.e004530.36","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133683","article-title":"Effects of Sacubitril\/Valsartan on the Renal Resistance Index","volume":"11","author":"Gioia","year":"2022","journal-title":"J Clin Med"},{"key":"2026100806101914000_13.2.e004530.37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/00015385.2019.1669317","article-title":"Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test","volume":"75","author":"Malfatto","year":"2020","journal-title":"Acta Cardiol"},{"key":"2026100806101914000_13.2.e004530.38","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020621","article-title":"Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril\/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology","volume":"12","author":"Cemin","year":"2023","journal-title":"J Clin Med"},{"key":"2026100806101914000_13.2.e004530.39","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000001202"},{"key":"2026100806101914000_13.2.e004530.40","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.ijcha.2020.100486","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry","volume":"27","author":"Correale","year":"2020","journal-title":"IJC Heart Vasc"},{"key":"2026100806101914000_13.2.e004530.41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122165","article-title":"The Effects of Sacubitril\/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The \u201cHemodynamic Recovery\u201d","volume":"8","author":"Romano","year":"2019","journal-title":"J Clin Med"},{"key":"2026100806101914000_13.2.e004530.42","article-title":"Effects and clinical implications of sacubitril\/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up","volume":"35","author":"Paolini","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026100806101914000_13.2.e004530.43","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1002\/ehf2.14107","article-title":"Clinical impacts of sacubitril\/valsartan on patients eligible for cardiac resynchronization therapy","volume":"9","author":"Huang","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026100806101914000_13.2.e004530.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2026100806101914000_13.2.e004530.45","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ejhf.2594","article-title":"Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?","volume":"24","author":"Abdelhamid","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026100806101914000_13.2.e004530.46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.561571"},{"key":"2026100806101914000_13.2.e004530.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211107"},{"key":"2026100806101914000_13.2.e004530.48","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12273"},{"key":"2026100806101914000_13.2.e004530.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2019.08.015"},{"key":"2026100806101914000_13.2.e004530.50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/ERP-16-0022","article-title":"Global longitudinal strain: a useful everyday measurement?","volume":"3","author":"King","year":"2016","journal-title":"Echo Res Pract"},{"key":"2026100806101914000_13.2.e004530.51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht160"},{"key":"2026100806101914000_13.2.e004530.52","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24085"},{"key":"2026100806101914000_13.2.e004530.53","unstructured":"Reeves JJ , Deeks JJ , Higgins JPT , et al . Chapter 24: including non-randomized studies on intervention effects. In: Cochrane handbook for systematic reviews of interventions. 2023. Available: www.training.cochrane.org\/handbook"},{"key":"2026100806101914000_13.2.e004530.54","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa645"},{"key":"2026100806101914000_13.2.e004530.55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2023.09.008","article-title":"Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure)","volume":"266","author":"Flett","year":"2023","journal-title":"Am Heart J"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2026-004530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:10:30Z","timestamp":1791465030000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2026-004530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/openhrt-2026-004530"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2026-004530","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}